Colombia
Tuberculosis profile
Population  2013 48 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.77 (0.75–0.78) 1.6 (1.6–1.6)
Mortality (HIV+TB only) 0.3 (0.21–0.42) 0.63 (0.43–0.87)
Prevalence  (includes HIV+TB) 21 (10–35) 43 (21–72)
Incidence  (includes HIV+TB) 16 (14–18) 32 (29–37)
Incidence (HIV+TB only) 1.5 (1.2–1.7) 3 (2.5–3.6)
Case detection, all forms (%) 75 (66–84)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.4 (1.6–3.6) 13 (9.6–17)
MDR-TB cases among notified pulmonary
TB cases
220 (140–320) 110 (84–140)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 6 996   388
Pulmonary, clinically diagnosed 1 999   0
Extrapulmonary 2 354   0
       
Total new and relapse 11 737    
Previously treated, excluding relapses 485    
Total cases notified 12 222    
Among 11 737 new and relapse cases:
571 (5%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 4 758 (68%) 188 (22%) 6 587
Laboratory-confirmed RR-/MDR-TB cases     165
Patients started on MDR-TB treatment     152
TB/HIV 2013 Number (%)
TB patients with known HIV status 8 992 (74)
HIV-positive TB patients 1 226 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 489 (40)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 72
Previously treated cases registered in 2012 51
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 49
XDR-TB cases started on second-line treatment in 2011 22
Laboratories 2013  
Smear (per 100 000 population) 5.6
Culture (per 5 million population) 111.1
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 10
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 11
% Funded domestically 68%
% Funded internationally 32%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-04 Data: www.who.int/tb/data